Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, H2 2020 - Therapeutic Analysis Report Featuring 50+ Companies - ResearchAndMarkets.com

The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Chronic Obstructive Pulmonary Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 8, 34, 13, 3, 82, 22 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Key Topics Covered:

• Introduction
• Chronic Obstructive Pulmonary Disease - Overview
• Chronic Obstructive Pulmonary Disease - Therapeutics Development
• Chronic Obstructive Pulmonary Disease - Therapeutics Assessment
• Chronic Obstructive Pulmonary Disease - Companies Involved in Therapeutics Development
• Chronic Obstructive Pulmonary Disease - Drug Profiles
• Chronic Obstructive Pulmonary Disease - Dormant Projects
• Chronic Obstructive Pulmonary Disease - Discontinued Products
• Chronic Obstructive Pulmonary Disease - Product Development Milestones
• Appendix

Companies Mentioned

• 3SBio Inc
• AB Science SA
• AB2 Bio Ltd
• Adamis Pharmaceuticals Corp
• Afimmune Biopharma Ltd
• Aibios Co Ltd
• AlgiPharma AS
• Allinaire Therapeutics LLC
• Amgen Inc
• Angiocrine Bioscience Inc
• Apollo Therapeutics LLC
• Aquilon Pharmaceuticals SA
• Aridis Pharmaceuticals Inc
• Ark Biosciences Inc
• Arrowhead Pharmaceuticals Inc
• AstraZeneca Plc
• Atriva Therapeutics GmbH
• AusBio Ltd
• Avidin Biotechnology Ltd
• Axolo Pharma Inc
• Bai Shuo Beijing Pharmaceutical Technology Co Ltd
• Bayer AG
• BioMarck Pharmaceuticals Ltd
• Boehringer Ingelheim International GmbH
• Brickell Biotech Inc
• C4X Discovery Holdings Plc
• Cambryn Biologics LLC
• Celon Pharma SA
• Chiesi Farmaceutici SpA
• Cipla Ltd
• Circassia Group Plc
• Covenant Therapeutics LLC
• CSL Ltd
• Cureveda LLC
• Cytokinetics Inc
• Denovo Biopharma LLC
• Diadem Biotherapeutics Inc
• Diffusion Pharmaceuticals Inc
• Dimerix Ltd
• Domainex Ltd
• EmeraMed Ltd
• EmphyCorp Inc
• Emphymab Biotech LLC
• Enzychem Lifesciences Corp
• EpiEndo Pharmaceuticals Ehf
• Epitracker Inc
• Errant Gene Therapeutics LLC
• ethris GmbH
• Evaxion Biotech ApS
• Exotect LLC
• F. Hoffmann-La Roche Ltd
• Foresee Pharmaceuticals Co Ltd
• Future Medicine Co Ltd
• Galapagos NV

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nmamsp

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123006073/en/